Translate Bio

Translate Bio Overview

Founded 2010
Founded
Status Public
Employees 93
Employees
Stock Symbol TBIO
Stock Symbol
Investments 1
Share Price $21.02 (As of Tuesday Closing)

Translate Bio General Information

Description

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Contact Information

Formerly Known As
RaNA Therapeutics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 29 Hartwell Avenue
  • Lexington, MA 02421
  • United States
+1 (617) 000-0000

Translate Bio Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Translate Bio Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$21.02 $20.44 $6.80 - $21.95 $1.32B 62.9M 607K -$1.73

Translate Bio Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 422,430 291,136 177,466
Revenue 10,984 7,804 1,420 0
EBITDA (91,318) (111,057) (101,442) (77,620)
Net Income (94,377) (113,293) (97,395) (66,443)
Total Assets 305,242 336,201 287,651 198,547
Total Debt 12,504 12,614 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Translate Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Translate Bio‘s full profile, request access.

Request a free trial

Translate Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Translate Bio‘s full profile, request access.

Request a free trial

Translate Bio Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
OncoResponse Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
00000 000000000 Formerly VC-backed South San Francisco, CA 000 00000 000000 - 000 00000
00000000000 Angel-Backed Culver City, CA 00000 000000000000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 000.00 0000000000 0 000.00
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 00000000 00000

Translate Bio Executive Team (17)

Name Title Board Seat Contact Info
Ronald Renaud Jr. Chief Executive Officer & Board Member
John Schroer Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Paul Burgess JD Chief Operating Officer, Operations & Secretary, Administration
Richard Wooster Ph.D Chief Scientific Officer
Michael Heartlein Ph.D Executive Vice President & Founder

9 Former Executives

Translate Bio Board Members (16)

To view Translate Bio‘s full board member team, request access >>
Name Representing Role Since
Ankit Mahadevia MD Atlas Venture Board Member 000 0000
Daniel Lynch Self Chairman & Board Member 000 0000
George Demetri MD Self Board Member 000 0000
Iain Dukes Ph.D Self Board Member 000 0000
Jean-Francois Formela MD Self Board Member 000 0000

8 Former Board Members

Translate Bio Investments (1)

To view Translate Bio‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 (000 0000000 04-Jan-2017 000000000 00000 00 Biotechnology 000000 000000 00.